H.C. Wainwright analyst Raghuram Selvaraju downgraded CervoMed (CRVO) to Neutral from Buy without a price target saying the “disappointing” neflamapimod clinical data “creates uncertainty.” The cites the RewinD-LB study failure for the downgrade.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO: